ATE420201T1 - Nachweis der cox-2 aktivität und von anandamid- metaboliten - Google Patents

Nachweis der cox-2 aktivität und von anandamid- metaboliten

Info

Publication number
ATE420201T1
ATE420201T1 AT01963833T AT01963833T ATE420201T1 AT E420201 T1 ATE420201 T1 AT E420201T1 AT 01963833 T AT01963833 T AT 01963833T AT 01963833 T AT01963833 T AT 01963833T AT E420201 T1 ATE420201 T1 AT E420201T1
Authority
AT
Austria
Prior art keywords
cox
activity
detection
kits
prostaglandin
Prior art date
Application number
AT01963833T
Other languages
English (en)
Inventor
Lawrence Marnett
Kevin Kozak
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE420201T1 publication Critical patent/ATE420201T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01963833T 2000-08-07 2001-08-07 Nachweis der cox-2 aktivität und von anandamid- metaboliten ATE420201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22366500P 2000-08-07 2000-08-07
US30297501P 2001-07-03 2001-07-03

Publications (1)

Publication Number Publication Date
ATE420201T1 true ATE420201T1 (de) 2009-01-15

Family

ID=26918005

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01963833T ATE420201T1 (de) 2000-08-07 2001-08-07 Nachweis der cox-2 aktivität und von anandamid- metaboliten
AT01963827T ATE421595T1 (de) 2000-08-07 2001-08-07 Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01963827T ATE421595T1 (de) 2000-08-07 2001-08-07 Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten

Country Status (7)

Country Link
US (3) US7189504B2 (de)
EP (2) EP1307585B1 (de)
AT (2) ATE420201T1 (de)
AU (3) AU8474701A (de)
CA (2) CA2422803A1 (de)
DE (2) DE60137335D1 (de)
WO (2) WO2002012549A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8414774B2 (en) * 2001-04-25 2013-04-09 Agilent Technologies, Inc. Systems and methods for high-throughput screening of fluidic samples
WO2009059286A1 (en) * 2007-11-02 2009-05-07 Biotrove, Inc. Devices and methods for coupling mass spectrometry devices with chromatography systems
US20050123970A1 (en) * 2001-04-25 2005-06-09 Can Ozbal High throughput autosampler
AU2002354901A1 (en) * 2001-07-16 2003-03-03 Edward Hogestatt Compounds with analgesic, antipyretic and/or anti-inflammatory activity
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
CA2495587A1 (en) * 2002-08-22 2004-03-04 Cornell Research Foundation, Inc. Multifunctional cox-2 inhibitors
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
GB0402719D0 (en) * 2004-02-07 2004-03-10 Royal College Of Surgeons Ie A method of detecting incomplete inhibition of enzymes in individuals undergoing enzyme inhibitor therapy
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
WO2009105481A1 (en) * 2008-02-19 2009-08-27 The Buck Institute For Age Research Mao-b elevation as an early parkinson's disease biomarker
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
CA2968757A1 (en) * 2014-12-09 2016-06-16 Nestec S.A. Uses of bioactive lipids
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
AU2018324070B2 (en) 2017-09-01 2023-05-18 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
CN109900830B (zh) * 2019-04-02 2021-07-23 天地恒一制药股份有限公司 采用hplc分离测定塞来昔布中磺酰胺类杂质的方法及应用
US12518880B1 (en) * 2021-12-21 2026-01-06 Karim I. Budhwani Post-mortem multimodal tumor supermodel
CN117007728B (zh) * 2023-06-12 2025-10-17 黑龙江飞鹤乳业有限公司 一种母乳或奶粉样本中常见游离氧化脂质及其前体化合物同时分析的方法
CN119064507B (zh) * 2024-09-07 2025-06-27 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 测定炎症模型中花生四烯酸代谢通路cox-2代谢产物含量的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632627A (en) 1968-01-05 1972-01-04 Smith Kline French Lab Glyceride derivatives of prostaglandins
JPS4920766B1 (de) 1970-11-10 1974-05-27
CA932324A (en) 1971-10-22 1973-08-21 Gordon Maxwell Glyceride and phosphatide derivatives of prostaglandins
JPS59156299A (ja) * 1983-02-28 1984-09-05 Noda Sangyo Kagaku Kenkyusho Ｎ−アセチルヘキソサミンの定量法及びその定量用試薬
US4675281A (en) 1984-07-09 1987-06-23 Lands William E M Quantification of hydroperoxides using prostaglandin H synthase
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US5047354A (en) 1987-10-30 1991-09-10 Foegh Marie L Thromboxane B2 assay for coronary artery thrombosis
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5858696A (en) 1991-06-14 1999-01-12 Vanderbilt University Method and compositions to assess oxidative stress in vivo
WO1992022668A1 (en) 1991-06-14 1992-12-23 Vanderbilt University Method and compositions to assess oxidative stress in vivo
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5589575A (en) 1992-07-23 1996-12-31 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture Purification of hapten-carrier generated antibodies
US5837479A (en) 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
ATE123151T1 (de) 1992-10-21 1995-06-15 Edith Dr Dr Huland Verfahren zur quantitativen bestimmung von krankheitsspezifischen antigenen und vorrichtung zur durchführung des verfahrens.
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5995645A (en) 1993-08-18 1999-11-30 Applied Spectral Imaging Ltd. Method of cancer cell detection
US5475021A (en) * 1993-12-03 1995-12-12 Vanderbilt University Compounds and compositions for inhibition of cyclooxygenase activity
US5459239A (en) 1994-01-24 1995-10-17 Merck Frosst Canada Inc. Peptide sequences and antipeptide antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 proteins
US5686269A (en) * 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US5999843A (en) 1995-01-03 1999-12-07 Omnicorder Technologies, Inc. Detection of cancerous lesions by their effect on the spatial homogeneity of skin temperature
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
FR2732597B1 (fr) * 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
KR19990064310A (ko) * 1995-10-17 1999-07-26 윌리암스 로저 에이 시클로옥시게나제-2의 검출방법
US5945675A (en) 1996-03-18 1999-08-31 Pacific Northwest Research Foundation Methods of screening for a tumor or tumor progression to the metastatic state
US5891622A (en) 1996-09-30 1999-04-06 Oxford Biomedical Research, Inc. Assessment of oxidative stress in vivo
IL121659A (en) 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
US5858694A (en) 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5874235A (en) * 1997-07-18 1999-02-23 The Johns Hopkins University Screening assays for cancer chemopreventative agents
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use

Also Published As

Publication number Publication date
EP1307538B1 (de) 2009-01-07
US7628975B2 (en) 2009-12-08
EP1307585B1 (de) 2009-01-21
ATE421595T1 (de) 2009-02-15
AU8474701A (en) 2002-02-18
DE60137335D1 (de) 2009-02-26
US20060110786A1 (en) 2006-05-25
WO2002012445A1 (en) 2002-02-14
AU8475301A (en) 2002-02-18
US20020064804A1 (en) 2002-05-30
CA2422306A1 (en) 2002-02-14
EP1307585A4 (de) 2005-03-02
EP1307538A1 (de) 2003-05-07
US20020106707A1 (en) 2002-08-08
EP1307585A1 (de) 2003-05-07
DE60137512D1 (de) 2009-03-12
AU2001284753B2 (en) 2006-10-26
US7189504B2 (en) 2007-03-13
WO2002012549A1 (en) 2002-02-14
CA2422803A1 (en) 2002-02-14
EP1307538A4 (de) 2005-03-02

Similar Documents

Publication Publication Date Title
ATE420201T1 (de) Nachweis der cox-2 aktivität und von anandamid- metaboliten
Haan et al. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background
DK1381697T3 (da) Cirkulær probe-amplifikation (CPA) af ringformede nukleinsyremolekyler
ES2715018T3 (es) Ensayo múltiple para puntuar mejor los tejidos tumorales teñidos para PD-L1
DE60134957D1 (de) Methoden und testsätze für annäherungstest
JP2004503760A5 (de)
Yang et al. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2-and 3-series prostaglandins in cultured tumor cells
RU2003100531A (ru) Композиции, содержащие краситель на основе производного мочевины, для выявления аналита, и способы их использования
DK420387D0 (da) Fremgangsmaade og hybridiseringsproevesaet til paavisning af en nucleotidmaalsekvens
EP1664783A4 (de) Schnelltest für glykiertes albumin
BRPI0710054B8 (pt) métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste
BRPI0412545A (pt) analisador de múltiplas detecções automatizado
WO2004027378A3 (en) Luminescence-based methods and probes for measuring cytochrome p450 activity
DK2082238T3 (da) Sekventiel analyse af biologiske prøver med intermediær fluorescensdetektorblegning
DK1639130T3 (da) Prober, biblioteker og kits til analyse af blandinger af nukleinsyrer og metoder til opbygning af disse
Yuan et al. Subsecond absolute quantitation of amine metabolites using isobaric tags for discovery of pathway activation in mammalian cells
Ciscato et al. The chemiluminescent peroxyoxalate system: state of the art almost 50 years from its discovery.
BR0101294A (pt) Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores
MX2022005159A (es) Uso de biomarcadores para predecir la sensibilidad clinica a 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida.
TW200745551A (en) Device and methods for detecting and quantifying one or more target agents
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
RU2016143733A (ru) Применение абсорбирующих частиц для усовершенствования обнаружения сигнала в способе анализа
NO20073524L (no) En metode for differensiering mellom blod og kontrollopplosninger som inneholder en vanlig analytt
Glauser et al. Enzyme and acid deconjugation of plasma sulfated metanephrines
Yu et al. A [32P] NAD+-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties